Chris Peetz is a co-founder of Mirum and serves as president and chief executive officer.
Chris has been an entrepreneur-in-residence at Frazier Healthcare Partners since May 2017. Prior to joining Mirum, Chris served as the chief executive officer of Flashlight Therapeutics, Inc. From May 2014 to December 2016, he served as chief financial officer and head of corporate development at Tobira, which was acquired by Allergan plc, in November 2016. Prior to joining Tobira, Chris served as vice president, finance and corporate development of Jennerex Biotherapeutics. Prior to Jennerex, Chris held various positions at Onyx Pharmaceuticals, Inc. (now Amgen Inc.), including corporate strategy, marketing, product lifecycle management, and financial planning. Prior to Onyx, Chris provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. He also serves as a member of the board of directors of Alpine Immune Sciences, Inc., a public immunotherapy company, since April 2018.
Chris received an M.B.A. from Stanford Graduate School of Business and a B.S.B.A. in Finance, International Business and French from Washington University in St. Louis.
What is Christopher Peetz's net worth?
The estimated net worth of Christopher Peetz is at least $16.90 million as of February 2nd, 2026. Mr. Peetz owns 160,294 shares of Mirum Pharmaceuticals stock worth more than $16,903,002 as of February 3rd. This net worth evaluation does not reflect any other investments that Mr. Peetz may own. Additionally, Mr. Peetz receives a salary of $1,310,000.00 as Co-Founder, CEO and Director at Mirum Pharmaceuticals. Learn More about Christopher Peetz's net worth.
How old is Christopher Peetz?
What is Christopher Peetz's salary?
How do I contact Christopher Peetz?
Has Christopher Peetz been buying or selling shares of Mirum Pharmaceuticals?
During the past quarter, Christopher Peetz has sold $2,260,386.63 in Mirum Pharmaceuticals stock. Most recently, Christopher Peetz sold 9,108 shares of the business's stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $103.30, for a transaction totalling $940,856.40. Following the completion of the sale, the chief executive officer now directly owns 160,294 shares of the company's stock, valued at $16,558,370.20. Learn More on Christopher Peetz's trading history.
Who are Mirum Pharmaceuticals' active insiders?
Mirum Pharmaceuticals' insider roster includes Eric Bjerkholt (CFO), Laura Brege (Director), Ian Clements (CFO), James Flynn (Major Shareholder), Michael Grey (Chairman of the Board), Patrick Heron (Director), Jolanda Howe (SVP), Lara Longpre (Chief Development Officer), Christopher Peetz (Co-Founder, CEO and Director), Joanne Quan (Chief Medical Officer), Peter Radovich (President & Chief Operating Officer), Saira Ramasastry (Director), and Pamela Vig (Insider). Learn More on Mirum Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Mirum Pharmaceuticals?
During the last twelve months, Mirum Pharmaceuticals insiders bought shares 2 times. They purchased a total of 132,760 shares worth more than $9,060,819.95. During the last twelve months, insiders at the sold shares 26 times. They sold a total of 268,312 shares worth more than $16,391,517.03. The most recent insider tranaction occured on February, 2nd when COO Peter Radovich sold 2,631 shares worth more than $271,782.30. Insiders at Mirum Pharmaceuticals own 22.9% of the company.
Learn More about insider trades at Mirum Pharmaceuticals. Information on this page was last updated on 2/2/2026.
